Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion

0

Employees

0

Patents and patent applications

0

Biosimilars under development

Fraudulent attempts to use Xbrane's name


We want to inform our customers, partners, and other stakeholders that we have become aware of fraudulent attempts to use Xbrane’s name, particularly fake recruitment services. We take the security of our customers and business relationships very seriously and, therefore, emphasize the importance of remaining vigilant.

Please note that Xbrane does not engage in external advertisements for recruitment purposes. Our official recruitment communication channels are limited to our website (https://www.xbrane.com), email addresses ending with @xbrane.com, and our company page on LinkedIn (https://www.linkedin.com/company/xbrane-bioscience-ab).

Interview with CEO Martin Åmark, October 2023


At Xbrane Biopharma


Press Releases

22 May 2024

Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® – and run an active partnering process

16 May 2024

Xbrane Biopharma releases Interim Report for January-March 2024

13 May 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024

10 May 2024

Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US

02 May 2024

Announcement from Xbrane Biopharma’s annual general meeting

21 Apr 2024

Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate

02 Apr 2024

Notice of annual general meeting in Xbrane Biopharma AB

01 Apr 2024

Change of number of shares and votes in Xbrane

27 Mar 2024

XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2023